Abstract 2989
Background
Past and recent findings indicate that adverse effects of chemotherapy influence the patients’ quality of life. The aim of this study was to investigate the implicated factors that influenced the perceived symptoms and quality of life in cancer patients during chemotherapy.
Methods
A longitudinal study was conducted in a large hospital in a major city of Northern Greece. A total of 200 cancer patients undergoing chemotherapy in cycle 2 and cycle 3 were participated in the research. Data was collected using Memorial Symptom Assessment Scale (MSAS), Functional Assessment Cancer Therapy (FACT-G) additionally with a questionnaire for the demographic and clinical characteristics. Descriptive and conductive statistical methods were applied.
Results
The vast majority of the participants were middle aged (58.94±9.94 years) men (n = 122, 61%) suffering from lung cancer (n = 98, 48%). Analysis based on the chemotherapy cycle status revealed a significant differences in several factors grouping the patients regarding their chemotherapy cycle status (cycle 2 vs cycle 3). Particularly, feeling nervous level, severity and distress of dizziness and the severity in the way of food tastes [p = 0.014, p = 0.001, p < 0.001, p < 0.001 and p = 0.030, respectively] differed statistically significantly. Moreover, multiple logistic regression analysis revealed that gender (p < 0.001) and physical well-being score (p = 0.005) affected perceived symptoms in MSAS. Furthermore, gender, occupational status, diet, type of cancer and family status influenced the overall quality of life in cycle 2 patients (p = 0.002, p < 0.001, p = 0.002, p < 0.001 and p < 0.001 respectively); however, in cycle 3 patients : gender (p = 0.003), occupational status (p < 0.001), educational status (p < 0.001) and diet (p < 0.001) were referred as the most statistically significant variables that influence the overall quality of life.
Conclusions
In conclusion, we demonstrate that adverse effects of chemotherapy in cancer patients play a critical role for the overall quality of patients’ life. Patients demographic or/ and clinicobiological characteristics seem to influence the appearance of the adverse effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract